Tagala, Severina .

HRN: 11-87-29  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/14/2025
CO-AMOXICLAV 625MG (TAB)
06/14/2025
06/17/2025
PO
625 Mg/tab
TID
Pneumonia
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: